Lacnotuzumab

Names

[ Name ]:
Lacnotuzumab

Biological Activity

[Description]:

Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonal antibody targeting CSF-1 that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis[1][2].

[Related Catalog]:

Research Areas >> Cancer

Research Areas >> Metabolic Disease

Signaling Pathways >> Protein Tyrosine Kinase/RTK >> c-Fms

[Target]

CSF-1[1]

[In Vivo]

Lacnotuzumab 中和食蟹猴重组和血清衍生形式的 CSF-1，但它不识别啮齿动物或兔的 CSF-1[2]。

[References]

[1]. Kuemmel S, et, al. A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer. Clin Cancer Res. 2022 Jan 1;28(1):106-115.

[2]. Pognan F, et, al. Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes. J Pharmacol Exp Ther. 2019 Jun;369(3):428-442.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.